Loading organizations...
Nura Bio was conceived in 2018 to revolutionize the treatment of neurological diseases with novel, life-changing neuroprotective medicines.
Nura Bio has raised $68.0M across 1 funding round.
Nura Bio has raised $68.0M in total across 1 funding round.
Nura Bio has raised $68.0M in total across 1 funding round.
Nura Bio's investors include The Column Group, Dimension Capital, Lux Capital.
Nura Bio has raised $68.0M across 1 funding round. Most recently, it raised $68.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $68M Series A | The Column Group | Dimension Capital, LUX Capital | Announced |
Nura Bio is a clinical-stage biotechnology company developing small-molecule neuroprotective medicines targeting axon degeneration and neuroimmune regulation to treat neurological diseases, including peripheral, central, and ocular nervous system disorders.[1][3][5] Its lead product, NB-4746, is a brain-penetrant SARM1 inhibitor in Phase 1 clinical trials, designed to prevent axonal damage and provide neuroprotection, with the company serving patients suffering from debilitating neurodegenerative conditions where early axon loss drives disease progression.[1][2][3] Founded in 2018 and based in South San Francisco, Nura Bio has raised approximately $73 million in Series A funding (including a $68 million extension), employs 11-50 people, and operates a fully integrated drug discovery engine advancing candidates from target validation to the clinic.[1][4][6]
Nura Bio was conceived in 2018 by The Column Group, a biotech venture firm, alongside its scientific co-founders Marc Freeman, PhD, and Steve McKnight, PhD, who made seminal discoveries revealing SARM1 as a druggable, injury-activated NAD hydrolase central to the Wallerian degeneration pathway in axons.[3][4] These breakthroughs emerged from their labs, showing that SARM1 acts as an axon-intrinsic metabolic sensor driving catastrophic degeneration post-injury, with SARM1 knockout proving neuroprotective in preclinical models by preserving neuronal structure and function.[3] Early traction came from this foundational science, leading to rapid pipeline development; the company launched with a focus on transforming these insights into medicines, securing $73 million in Series A funding by July 2020 (including a major extension to support Phase 2 readiness for NB-4746).[1][2][4]
Nura Bio rides the wave of neurodegenerative disease innovation, targeting axon degeneration—a root cause in conditions like ALS, MS, and optic neuropathies—amid rising demand for disease-modifying therapies as global neurology markets exceed $100 billion, driven by aging populations and biomarkers like NfL.[1][3] Timing aligns with validated targets like SARM1, recently deorphaned via founder research, and advances in small-molecule CNS penetration, positioning Nura ahead of competitors in a field where regeneration remains inefficient.[3] Market forces favor it: surging VC interest in neuro biotech (e.g., post-2020 funding boom), CRO/CMO ecosystem in SF Bay, and regulatory nods for neuroprotection endpoints. Nura influences the ecosystem by validating Wallerian pathways, potentially inspiring platforms for immune-modulating neurotherapies and attracting talent/partnerships in the neuroinflammation space.[2][5]
Nura Bio's path forward centers on NB-4746 data readouts, likely Phase 2 trials in 2026 targeting optic neuritis or chemotoxicity models, with parallel expansion of its neuron-glia programs into combo therapies.[1][2][3] Trends like AI-driven target discovery, biomarker integration (NfL/MRI), and big pharma neuro M&A will accelerate its trajectory, potentially yielding proof-of-concept in 2-3 years if SARM1 inhibition translates clinically. Its influence could evolve from pipeline pioneer to category leader, redefining neuroprotection and offering hope against axon-driven decline—echoing its mission to free minds and bodies from neurological confines.[5]
